A mathematical insight to control the disease psoriasis using mesenchymal stem cell transplantation with a biologic inhibitor.
Mesenchymal stromal cells
Optimal control
Pulsed manner
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 09 2024
19 09 2024
Historique:
received:
18
01
2024
accepted:
26
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
epublish
Résumé
Psoriasis is a chronic, non-contagious, immune-mediated skin disorder. Inflammation of the skin's surface is characterised by scaly white, red, or silvery spots that occur due to the hyper-proliferation of keratinocytes in the epidermal layer. Primarily, pharmaceutical drugs or immune therapy are used to treat psoriasis. We are all aware that, certain therapeutic strategies can have some adverse effects, and over time, that hidden inflammation may manifest. This article introduces a mathematical model for psoriasis, formulated by employing a set of nonlinear ordinary differential equations (ODEs) that describe the densities of T-cells, dendritic cells (DCs), keratinocytes, and mesenchymal stromal cells (MSCs) as basic cell populations. A tumor necrosis factor-
Identifiants
pubmed: 39300232
doi: 10.1038/s41598-024-71251-3
pii: 10.1038/s41598-024-71251-3
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21897Subventions
Organisme : Project of National Statistical Science Foundation of China
ID : 2021LD01
Informations de copyright
© 2024. The Author(s).
Références
Michalek, I. M., Loring, B. & John, S. M. Global Report on Psoriasis (World Health Organization, 2016).
Roy, P. K., Roy, A. K., Khailov, E. N., Al Basir, F. & Grigorieva, E. V. A model of the optimal immunotherapy of psoriasis by introducing il-10 and il-22 inhibitors. J. Biol. Syst. 28, 609–639 (2020).
doi: 10.1142/S0218339020500084
Iskandar, I., Parisi, R., Griffiths, C., Ashcroft, D. & Atlas, G. P. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br. J. Dermatol. 184, 243–258 (2021).
doi: 10.1111/bjd.19169
pubmed: 32358790
Menter, A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 58, 826–850 (2008).
doi: 10.1016/j.jaad.2008.02.039
pubmed: 18423260
Britannica, T. Editors of encyclopaedia. Argon. Encycl. Britannica (2020).
Sierra-Sánchez, Á., Montero-Vilchez, T., Quiñones-Vico, M. I., Sanchez-Diaz, M. & Arias-Santiago, S. Current advanced therapies based on human mesenchymal stem cells for skin diseases. Front. Cell Dev. Biol. 9, 643125 (2021).
doi: 10.3389/fcell.2021.643125
pubmed: 33768095
pmcid: 7985058
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).
doi: 10.1038/s41573-022-00476-6
pubmed: 35637318
pmcid: 9149674
Cataldi, C. et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: Use as laboratory biomarkers and disease predictors. Inflamm. Res. 68, 557–567 (2019).
doi: 10.1007/s00011-019-01238-8
pubmed: 31062065
Gröne, A. Keratinocytes and cytokines. Vet. Immunol. Immunopathol. 88, 1–12 (2002).
doi: 10.1016/S0165-2427(02)00136-8
pubmed: 12088639
Puhr, S., Lee, J., Zvezdova, E., Zhou, Y. J. & Liu, K. Dendritic cell development—History, advances, and open questions. Semin. Immunol. 27, 388–396 (2015).
doi: 10.1016/j.smim.2016.03.012
pubmed: 27040276
Cheng, L. et al. Human umbilical cord mesenchymal stem cells for psoriasis: A phase 1/2a, single-arm study. Signal Transduct. Target. Ther. 7, 263 (2022).
doi: 10.1038/s41392-022-01059-y
pubmed: 35927231
pmcid: 9352692
Ullah, I., Subbarao, R. B. & Rho, G. J. Human mesenchymal stem cells-current trends and future prospective. Biosci. Rep. 35, e00191 (2015).
doi: 10.1042/BSR20150025
pubmed: 25797907
pmcid: 4413017
Blanco, P., Palucka, A. K., Pascual, V. & Banchereau, J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 19, 41–52 (2008).
doi: 10.1016/j.cytogfr.2007.10.004
pubmed: 18258476
pmcid: 2413068
Xu, M. et al. Regulation of antitumor immune responses by the il-12 family cytokines, il-12, il-23, and il-27. Clin. Dev. Immunol. 2010, 832454 (2010).
pubmed: 20885915
pmcid: 2946577
Coimbra, S., Figueiredo, A., Castro, E., Rocha-Pereira, P. & Santos-Silva, A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int. J. Dermatol. 51, 389–398 (2012).
doi: 10.1111/j.1365-4632.2011.05154.x
pubmed: 22435425
Datta, A. & Roy, P. K. T-cell proliferation on immunopathogenic mechanism of psoriasis: A control based theoretical approach. Control. Cybern. 42, 365–386 (2013).
Hawkes, J. E., Yan, B. Y., Chan, T. C. & Krueger, J. G. Discovery of the il-23/il-17 signaling pathway and the treatment of psoriasis. J. Immunol. 201, 1605–1613 (2018).
doi: 10.4049/jimmunol.1800013
pubmed: 30181299
Roy, A. K., Al Basir, F. & Roy, P. K. A vivid cytokines interaction model on psoriasis with the effect of impulse biologic (tnf- α inhibitor) therapy. J. Theor. Biol. 474, 63–77 (2019).
doi: 10.1016/j.jtbi.2019.04.007
pubmed: 30980871
Roy, A. K., Al Basir, F., Roy, P. K. & Chatterjee, A. N. A model analysis to measure the adherence of etanercept and fezakinumab therapy for the treatment of psoriasis. Nonlinear Anal. Model. Control 27, 513–533 (2022).
Lwin, S., Snowden, J. & Griffiths, C. The promise and challenges of cell therapy for psoriasis. Br. J. Dermatol. 185, 887–898 (2021).
doi: 10.1111/bjd.20517
pubmed: 34036569
Owczarczyk-Saczonek, A. et al. Stem cells as potential candidates for psoriasis cell-replacement therapy. Int. J. Mol. Sci. 18, 2182 (2017).
doi: 10.3390/ijms18102182
pubmed: 29053579
pmcid: 5666863
Asadullah, K. et al. Il-10 is a key cytokine in psoriasis. Proof of principle by il-10 therapy: A new therapeutic approach. J. Clin. Investig. 101, 783–794 (1998).
doi: 10.1172/JCI1476
pubmed: 9466973
pmcid: 508626
Bassi, E. J., de Almeida, D. C., Moraes-Vieira, P. M. M. & Câmara, N. O. S. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Rev. Rep. 8, 329–342 (2012).
doi: 10.1007/s12015-011-9311-1
pubmed: 21881832
Campanati, A. et al. Role of mesenchymal stem cells in the pathogenesis of psoriasis: Current perspectives. Psoriasis Targets Ther. 7, 73–85 (2017).
doi: 10.2147/PTT.S108311
Shin, T.-H., Kim, H.-S., Choi, S. W. & Kang, K.-S. Mesenchymal stem cell therapy for inflammatory skin diseases: Clinical potential and mode of action. Int. J. Mol. Sci. 18, 244 (2017).
doi: 10.3390/ijms18020244
pubmed: 28125063
pmcid: 5343781
Albanesi, C., Madonna, S., Gisondi, P. & Girolomoni, G. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front. Immunol. 9, 1549 (2018).
doi: 10.3389/fimmu.2018.01549
pubmed: 30034395
pmcid: 6043636
Lin, L. & Du, L. The role of secreted factors in stem cells-mediated immune regulation. Cell Immunol. 326, 24–32 (2018).
doi: 10.1016/j.cellimm.2017.07.010
pubmed: 28778535
Han, Y. et al. Mesenchymal stem cells for regenerative medicine. Cells 8, 886 (2019).
doi: 10.3390/cells8080886
pubmed: 31412678
pmcid: 6721852
Zhang, Y., Yan, J., Li, Z., Zheng, J. & Sun, Q. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate psoriasis-like skin inflammation. J. Interferon Cytokine Res. 42, 8–18 (2022).
doi: 10.1089/jir.2021.0146
pubmed: 35041513
Pittenger, M. F. et al. Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen. Med. 4, 22 (2019).
doi: 10.1038/s41536-019-0083-6
pubmed: 31815001
pmcid: 6889290
Roy, A. K., Roy, P. K. & Grigorieva, E. Mathematical insights on psoriasis regulation: Role of th1 and th2 cells. Math. Biosci. Eng. 15, 717–738 (2017).
Roy, A. K., Nelson, M. & Roy, P. K. A control-based mathematical study on psoriasis dynamics with special emphasis on il- 21 and ifn- γ interaction network. Math. Methods Appl. Sci. 44, 13403–13420 (2021).
doi: 10.1002/mma.7635
Zhang, H. et al. Modelling epidermis homoeostasis and psoriasis pathogenesis. J. R. Soc. Interface 12, 20141071 (2015).
doi: 10.1098/rsif.2014.1071
pubmed: 25566881
pmcid: 4305409
Nagumo, M. Über die lage der integralkurven gewöhnlicher differentialgleichungen. Proc. Phys. Math. Soc. Jpn. 3rd Ser. 24, 551–559 (1942).
Birkhoff, G. & Rota, G. Ordinary Differential Equation (Ginn and Co, 1982).
DeJesus, E. X. & Kaufman, C. Routh-hurwitz criterion in the examination of eigenvalues of a system of nonlinear ordinary differential equations. Phys. Rev. A 35, 5288 (1987).
doi: 10.1103/PhysRevA.35.5288
Schättler, H. & Ledzewicz, U. Optimal control for mathematical models of cancer therapies. In An Application of Geometric Methods (eds Schättler, H. & Ledzewicz, U.) (Springer, 2015).
Otero, J. G., Alcami, A.A.-A. & Belmonte-Beitia, J. Dynamics and analysis of a mathematical model of neuroblastoma treated with celyvir. Appl. Math. Model. 110, 131–148 (2022).
doi: 10.1016/j.apm.2022.05.038
Tobin, A.-M. & Kirby, B. Tnfα inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19, 47–57 (2005).
doi: 10.2165/00063030-200519010-00006
pubmed: 15691217
Saltelli, A., Tarantola, S. & Chan, K.-S. A quantitative model-independent method for global sensitivity analysis of model output. Technometrics 41, 39–56 (1999).
doi: 10.1080/00401706.1999.10485594